📗 Cite This Artifact
FANCA Gene
FANCA — Fanconi Anemia Group A
Introduction
FANCA (Fanconi Anemia Group A) is one of the most critical DNA repair genes in the human genome, encoding the core component of the Fanconi anemia (FA) pathway. This gene is essential for maintaining genomic stability through the repair of DNA interstrand crosslinks (ICLs), and its dysfunction has profound implications for both cancer predisposition and neurodegenerative diseases. The FA pathway has emerged as a crucial link between DNA damage repair defects and the progressive neuronal loss observed in Parkinson's disease (PD), Alzheimer's disease (AD), and other neurodegenerative conditions.
FANCA — Fanconi Anemia Group A
Introduction
FANCA (Fanconi Anemia Group A) is one of the most critical DNA repair genes in the human genome, encoding the core component of the Fanconi anemia (FA) pathway. This gene is essential for maintaining genomic stability through the repair of DNA interstrand crosslinks (ICLs), and its dysfunction has profound implications for both cancer predisposition and neurodegenerative diseases. The FA pathway has emerged as a crucial link between DNA damage repair defects and the progressive neuronal loss observed in Parkinson's disease (PD), Alzheimer's disease (AD), and other neurodegenerative conditions.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Fanconi Anemia Group A</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>FANCA</td></tr>
<tr><td><strong>Full Name</strong></td><td>Fanconi Anemia Group A</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16q24.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[2175](https://www.ncbi.nlm.nih.gov/gene/2175)</td></tr>
<tr><td><strong>OMIM</strong></td><td>607139</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000188191</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O15360](https://www.uniprot.org/uniprot/O15360)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Fanconi Anemia, Breast Cancer, Parkinson's Disease, Alzheimer's Disease</td></tr>
</table>
</div>
Gene Structure and Evolution
The FANCA gene spans approximately 80 kb on chromosome 16q24.3 and comprises 43 exons encoding a 1635-amino acid protein with a molecular weight of approximately 180 kDa. The FANCA protein contains several critical functional domains, including an N-terminal region with multiple leucine-rich motifs (LRR) involved in protein-protein interactions, a central region harboring binding sites for FANCC and FANCF, and a C-terminal domain that facilitates nuclear localization and DNA binding.
Phylogenetic analysis reveals that FANCA is highly conserved across vertebrates, with orthologs identified in all mammalian species examined. The conservation extends to key functional domains, particularly the C-terminal region essential for DNA repair function, suggesting strong selective pressure maintaining genomic integrity functions throughout evolution.
Protein Structure and Function
The FA Core Complex
FANCA serves as the scaffold for the Fanconi anemia core complex, a multiprotein assembly comprising FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, and FANCM. This complex functions as an E3 ubiquitin ligase that orchestrates the DNA damage response. FANCA accounts for approximately 80% of all FA pathway defects, making it the most frequently mutated gene in Fanconi anemia patients.
The assembly process begins with the binding of FANCA to FANCC and FANCF, forming a ternary complex that stabilizes the individual components. This trimer then associates with additional core complex members, including FANCB, FANCG, and FANCL, which contains the critical RING finger domain with ubiquitin ligase activity.
DNA Interstrand Crosslink Repair
The primary function of the FA pathway is the repair of DNA interstrand crosslinks (ICLs), which are catastrophic DNA lesions that block both transcription and replication. ICLs can be caused by endogenous metabolic byproducts (such as aldehydes), environmental agents (including chemotherapeutic agents like mitomycin C and cisplatin), and cellular stress.
The repair process involves multiple coordinated steps:
Nuclear Localization and Dynamics
FANCA undergoes dynamic nucleocytoplasmic shuttling, with nuclear import mediated by importin-α/β and nuclear export controlled by CRM1. The protein contains a canonical nuclear localization signal (NLS) at residues 1335-1339 and nuclear export signal (NES) sequences. In response to DNA damage, FANCA exhibits rapid redistribution to DNA repair foci, where it colocalizes with γ-H2AX, RAD51, and BRCA1.
Expression Patterns
FANCA is expressed ubiquitously across all tissue types, with highest expression in rapidly proliferating tissues:
- Bone marrow: Highest expression, consistent with the essential role in hematopoiesis
- Testis: High expression, reflecting ongoing spermatogenesis
- Brain: Moderate expression in neurons and glia
- Liver, kidney, heart: Moderate expression
- Lung, pancreas: Lower basal expression
Within the brain, FANCA expression has been detected in the [substantia nigra](/brain-regions/substantia-nigra), [hippocampus](/brain-regions/hippocampus), and [cerebral cortex](/brain-regions/cortex), regions critically affected in neurodegenerative diseases. Immunohistochemical studies have shown that FANCA is present in both [dopaminergic neurons](/cell-types/dopaminergic-neurons) and [astrocytes](/cell-types/astrocytes), suggesting cell-type-specific functions in the brain.
Molecular Mechanisms in Neurodegeneration
DNA Damage Accumulation in Aging Neurons
Neurons are particularly vulnerable to DNA damage due to their post-mitotic state and high metabolic activity. Unlike dividing cells, neurons cannot rely on replication to dilute accumulated DNA lesions. The FA pathway becomes increasingly important as neurons age, as endogenous DNA damage accumulates from oxidative metabolism, mitochondrial dysfunction, and environmental insults.
Studies have demonstrated that FANCA expression decreases with age in human brain tissue, potentially compromising the DNA repair capacity of aging neurons. This age-related decline may contribute to the accumulation of DNA damage that precedes neuronal dysfunction and death in neurodegenerative diseases.
Mitochondrial Dysfunction and Oxidative Stress
The FA pathway intersects with mitochondrial function in several important ways:
- Reactive Oxygen Species (ROS): Mitochondrial dysfunction leads to increased ROS production, causing oxidative DNA damage that requires FA pathway repair.
- Mitochondrial DNA Repair: Recent evidence suggests components of the FA pathway may participate in mitochondrial DNA repair, though this remains an area of active investigation.
- Metabolic Regulation: FANCA has been shown to regulate glycolysis and mitochondrial respiration through effects on PGC-1α signaling.
In Parkinson's disease, mitochondrial dysfunction is a central pathogenic mechanism, with complex I deficiency being a hallmark finding in affected [dopaminergic neurons](/cell-types/dopaminergic-neurons). The convergence of mitochondrial dysfunction and impaired DNA repair creates a vicious cycle that accelerates neuronal death.
Protein Homeostasis and Autophagy
The FA pathway interacts with protein quality control systems that are critical for neuronal survival:
- Proteasome Function: FANCA has been shown to regulate proteasome activity, and FA pathway deficiency leads to accumulation of polyubiquitinated proteins.
- Autophagy: The FA pathway intersects with autophagy through regulation of mTOR signaling and lysosomal function.
- ER Stress: FA pathway dysfunction triggers endoplasmic reticulum stress responses that can lead to apoptotic cell death.
These connections are particularly relevant to neurodegenerative diseases characterized by protein aggregation, including Parkinson's disease (α-synuclein), Alzheimer's disease (amyloid-β, tau), and ALS (TDP-43, SOD1).
Disease Associations
Fanconi Anemia
Biallelic mutations in FANCA cause approximately 60% of all Fanconi anemia cases, making it the most common cause of this autosomal recessive disorder. Fanconi anemia is characterized by:
- Developmental abnormalities: Radial ray defects, microcephaly, growth retardation
- Bone marrow failure: Progressive pancytopenia, typically presenting in childhood
- Cancer predisposition: Dramatically increased risk of acute myeloid leukemia, solid tumors
- Neurological manifestations: In some patients, neurodevelopmental delay and progressive neurological decline
The severity of FA phenotype correlates with the nature of FANCA mutations, with null alleles causing more severe disease than missense mutations that retain partial function.
Parkinson's Disease
The relationship between FANCA and Parkinson's disease has emerged from multiple lines of evidence:
- Genetic Association Studies: GWAS have identified FANCA variants as risk factors for PD in multiple populations.
- DNA Repair Defects: Post-mortem studies of PD brain tissue show reduced FANCA expression and impaired FA pathway activity.
- Neuronal Vulnerability: Dopaminergic neurons in the substantia nigra show particular sensitivity to FA pathway inhibition.
- Alpha-Synuclein Interaction: FANCA has been shown to regulate α-synuclein aggregation through effects on DNA damage response signaling.
The mechanisms by which FA pathway dysfunction contributes to PD include:
Alzheimer's Disease
In Alzheimer's disease, FANCA dysfunction may contribute to:
- Amyloid-β toxicity: FA pathway activation has been shown to protect against amyloid-β-induced DNA damage.
- Tau pathology: DNA damage response activation may influence tau phosphorylation and aggregation.
- Neuronal death: The cumulative effect of DNA damage repair failure promotes apoptosis.
Amyotrophic Lateral Sclerosis (ALS)
Emerging evidence links FANCA to ALS pathogenesis:
- Oxidative DNA damage: ALS motor neurons show increased DNA oxidation.
- Impaired DNA repair: Patient-derived cells demonstrate FA pathway defects.
- C9orf72 interaction: The most common genetic cause of familial ALS involves genes that functionally intersect with the FA pathway.
Therapeutic Implications
Small Molecule Activators
The identification of compounds that activate the FA pathway represents a promising therapeutic strategy:
- FANCA agonists: Screening campaigns have identified small molecules that stabilize FANCA and enhance FA pathway activity.
- USP1 inhibitors: USP1 deubiquitinates FANCD2, and inhibitors can potentiate FA pathway activation.
- Checkpoint kinase inhibitors: Combining FA pathway activation with checkpoint inhibition may enhance therapeutic efficacy.
Gene Therapy Approaches
Gene therapy for FANCA deficiency has shown promise in preclinical models:
- Viral vector delivery: AAV vectors encoding FANCA have been used to restore FA pathway function in cell models.
- CRISPR-based approaches: Base editing and prime editing strategies to correct pathogenic FANCA mutations are under development.
- mRNA delivery: Lipid nanoparticle delivery of FANCA mRNA provides temporary pathway restoration.
Repurposing Opportunities
Existing drugs that modulate FA pathway activity may be repurposed for neurodegenerative disease:
- HDAC inhibitors: Some HDAC inhibitors activate FA pathway gene expression.
- PARP inhibitors: While caution is needed, controlled inhibition may enhance FA pathway engagement.
- Antioxidants: N-acetylcysteine and other antioxidants reduce DNA damage burden, potentially alleviating FA pathway strain.
Biomarker Potential
FANCA expression and activity have biomarker potential in neurodegenerative diseases:
- Diagnostic markers: FANCA levels in cerebrospinal fluid may serve as a biomarker for DNA repair defects.
- Disease progression: Serial measurement of FA pathway activity may track disease progression.
- Therapeutic monitoring: Response to FA pathway-targeting therapies may be assessed through pathway activity assays.
Research Directions
Single-Cell Analysis
Single-cell RNA sequencing of human brain tissue has revealed cell-type-specific expression patterns and regulation of FANCA. These studies have identified:
- Neuron-specific FANCA isoforms with distinct functional properties
- Glial cell populations with differential FA pathway activity
- Disease-associated changes in FANCA expression patterns
Induced Pluripotent Stem Cell Models
Patient-derived iPSC models have provided insights into FANCA function in disease:
- Motor neurons derived from FA patients show increased DNA damage sensitivity
- Dopaminergic neurons with FANCA deficiency exhibit mitochondrial dysfunction
- Cortical neurons demonstrate impaired proteostasis and increased apoptosis
Proteomics and Interactomics
Mass spectrometry-based studies have expanded the FANCA interaction network:
- Novel partners: Identification of previously unknown FANCA-interacting proteins
- Post-translational modifications: Phosphorylation, acetylation, and ubiquitination sites mapped
- Dynamic interactions: DNA damage-induced changes in the FANCA interactome characterized
Cross-Linking and Related Pathways
FANCA intersects with multiple other molecular pathways relevant to neurodegeneration:
- [DNA Repair Pathways](/mechanisms/dna-repair-pathways): The FA pathway works with homologous recombination, nucleotide excision repair, and translesion synthesis.
- [Homologous Recombination](/mechanisms/homologous-recombination): BRCA1/2-mediated recombination is the downstream repair pathway.
- [Oxidative Stress Response](/mechanisms/oxidative-stress): ROS-induced DNA damage is a major substrate for FA pathway repair.
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pd): Mitochondrial health and FA pathway function are interconnected.
- [Cell Cycle Checkpoints](/mechanisms/cell-cycle-checkpoints): FA pathway activation is coordinated with cell cycle regulation.
- [Apoptosis Pathways](/mechanisms/apoptosis-neurodegeneration): DNA damage-induced apoptosis is regulated by FA pathway activity.
See Also
- [FANCA Protein](/proteins/fanca-protein) - The FANCA protein
- [FANCD2](/genes/fancd2) - Fanconi Anemia Group D2
- [Fanconi Anemia Pathway](/mechanisms/fanconi-anemia-pathway) - The FA DNA repair pathway
- [Fanconi Anemia](/diseases/fanconi-anemia) - Fanconi anemia disease
- [Parkinson's Disease](/diseases/parkinsons-disease) - Neurodegenerative disease
- [DNA Repair Pathways](/mechanisms/dna-repair-pathways) - Overview of DNA repair
- [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-response-neurodegeneration) - DNA damage and neuronal death
External Links
- [NCBI Gene: FANCA](https://www.ncbi.nlm.nih.gov/gene/2175)
- [OMIM: FANCA](https://www.omim.org/entry/607139)
- [Ensembl: FANCA](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188191)
- [UniProt: FANCA](https://www.uniprot.org/uniprot/O15360)
- [GeneCards: FANCA](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FANCA)
- [PubMed: FANCA Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=FANCA+neurodegeneration+Parkinson)
- [Fanconi Anemia Research Fund](https://www.fanconi.org/)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving FANCA Gene discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-fanca |
| kg_node_id | FANCA |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-c00b15c175fb |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-fanca'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-fanca?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[FANCA Gene](http://scidex.ai/artifact/wiki-genes-fanca)
http://scidex.ai/artifact/wiki-genes-fanca